Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Andra Talaska

Physician Assistant, Medical Grand Rapids, MI Physician Assistant

NPI 1336537877 CMS profile 10838176

3210 Eagle Run Dr Ne, Grand Rapids, MI 49525

Open in the dashboard

General payments

$10,580

563 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andra Talaska of Grand Rapids, MI is reported in the CMS Open Payments database as having received $10,580 across 563 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,595 142
2024 General $1,704 94
2023 General $1,732 94
2022 General $2,297 112
2021 General $2,252 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andra Talaska
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Andra Talaska were reported at $2,595. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Andra Talaska Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,252 $156 $41–$563 $132
2022 $2,297 $185 $55–$649 $149
2023 $1,732 $199 $58–$717 $160
2024 $1,704 $206 $62–$740 $164
2025 $2,595 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $1,148 76 payments
  2. Novartis Pharmaceuticals Corporation $1,059 75 payments
  3. Abbott Laboratories $824 14 payments
  4. Amgen Inc. $656 37 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $652 39 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $647 34 payments
  7. Janssen Pharmaceuticals, Inc $540 36 payments
  8. Pfizer Inc. $507 26 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $493 24 payments
  10. Merck Sharp & Dohme Corporation $476 26 payments
  11. Other $3,576 176 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,412 559 payments
  2. Education $122 3 payments
  3. Gift $46 1 payment
Products named General payments · program years 2021–2025
  1. CAMZYOS $850 52 payments
  2. LEQVIO $734 55 payments
  3. LifeVest $652 39 payments
  4. Kerendia $647 34 payments
  5. XARELTO $540 36 payments
  6. VERQUVO $531 29 payments
  7. Repatha $517 29 payments
  8. VYNDAQEL $365 18 payments
  9. JARDIANCE $331 17 payments
  10. CLEVIPREX $316 10 payments
  11. Other $6,232 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,956

Median for Physician Assistant: 241

Drug cost

$568,199

Median for Physician Assistant: $4,110

Branded share of claims

30.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 159 $183,728
Camzyos Mavacamten Brand 20 $168,837
Entresto Sacubitril/Valsartan Brand 55 $70,253
Farxiga Dapagliflozin Propanediol Brand 36 $32,132
Jardiance Empagliflozin Brand 30 $31,698
Xarelto Rivaroxaban Brand 14 $19,586
Repatha Sureclick Evolocumab Brand 14 $19,048
Brilinta Ticagrelor Brand 22 $9,573
Metoprolol Succinate Generic 319 $8,518
Ezetimibe Generic 77 $2,824

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $243
$243 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $200
$200 20 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $139
$139 30 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $132
$132 — —
Repatha
  • Amgen Inc. $120
$120 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record